AMX0035 and Progressive Supranuclear Palsy

Clinical trial NCT06122662 · COMPLETED

Trial details

NCT number: NCT06122662
Sponsor: Amylyx Pharmaceuticals Inc.
Status: COMPLETED
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Progressive Supranuclear Palsy PSP Neurodegenerative Diseases Atypical Parkinsonism

Start date: 2023-12-21
Primary completion: 2025-09-30
Enrollment: 139

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.